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In this issue of Neuron, Lin et al. report that LRRK2 modulates age-related neurodegeneration caused by
overexpression of a-synuclein in the forebrain of transgenic mice. Overexpression of LRRK2 accelerates
the progression of a-synuclein-mediated neuropathological changes, whereas deletion of LRRK2 alleviates
these alterations. The results reveal an interesting interaction between a-synuclein and LRRK2, two gene
products linked to dominantly inherited Parkinson’s disease.Parkinson’s disease (PD) is the most
common neurodegenerative movement
disorder, affecting 5 million people
worldwide. PD is characterized clinically
by resting tremor, rigidity, bradykinesia,
and postural instability. The neuropatho-
logical hallmarks of PD are progressive
degeneration of dopaminergic (DA) neu-
rons and the presence of intraneuronal
cytoplasmic inclusions known as Lewy
bodies (LBs), though neuronal loss is
also seen in other neuronal groups, such
as noradrenergic neurons in the locus
coeruleus. The clinical manifestations of
PD are caused by degeneration of DA
neurons in the substantia nigra pars com-
pacta (SNpc), which results in dopamine
depletion in the striatum, as shown by
effective dopamine replacement therapy
during early phases of the disease.
The mechanisms underlying nigrostriatal
dopaminergic degeneration, however,
remain unresolved (Shen and Cookson,
2004).
During the last decade, mutations in at
least five distinct genes (a-synuclein,
parkin, DJ-1, PINK1, and LRRK2) have
been linked to familial PD, permitting
studies of the pathogenic mechanisms
using genetic approaches. A dominantly
inherited missense mutation (A53T) in
a-synuclein was the first to be linked to
early-onset familial PD. Subsequently,
additional missense and gene multiplica-
tion mutations were identified (Singleton,
2005), and a-synuclein was shown to be
a major constituent of LBs (Spillantini
et al., 1998), highlighting the importance
of a-synuclein in PD pathogenesis. a-Syn-
uclein is expressed at high levels in the
brain and is associated with presynaptic
vesicles. While the normal function ofa-synuclein is poorly understood, sev-
eral lines of transgenic mice overexpress-
ing wild-type or mutant a-synuclein have
been reported to develop neuronal
degeneration (Chandra et al., 2005; Gias-
son et al., 2002; Lee et al., 2002). How-
ever, none of them exhibits significant
degeneration of DA neurons in the SNpc
due to the predominant overexpression
of a-synuclein in non-DA neurons in these
transgenic mice.
More recently, several missense muta-
tions in the leucine-rich repeat kinase 2
(LRRK2) gene have been linked to auto-
somal dominantly inherited PD (Singleton,
2005), which are collectively the most
common genetic cause of late-onset PD.
While a-synuclein is a small protein of
140 amino acid residues with few func-
tional domains, LRRK2 is a large 2527
amino acid protein consisting of several
functional domains, including a leucine-
rich repeat domain, a Ras-like small
GTPase domain, and a kinase domain
with sequence homology to MAP kinase
kinase kinases. The pathogenic mutations
in LRRK2 are present in various functional
domains of the protein, and all affect
highly conserved amino acid residues.
Most LRRK2 mutations cause clinically
typical PD, but the neuropathological
features vary, ranging from pure nigral
degeneration without LBs to nigral degen-
eration with brainstem or widespread
LBs, or neurofibrillary tangles. Extensive
in vitro studies have shown increased
kinase activity associated with some
pathogenic mutations, such as the
G2019S mutation (Cookson et al., 2007).
In vivo studies using transgenic mice
overexpressing the R1441G mutant form
of LRRK2 or knockin mice expressingNeuron 64, Dthe R1441C mutant at endogenous levels
revealed deficits in dopamine release
and/or dopamine D2 receptor-mediated
function but absence of neurodegenera-
tion (Li et al., 2009; Tong et al., 2009).
The mechanism underlying these DA
functional defects is less clear.
How do mutations in five genes with
seemingly divergent functions cause
PD? While no common molecular path-
ways have emerged from studies of these
five gene products, genetic analysis of
recessive PD-linked gene products,
Parkin, DJ-1, and PINK1, in mice and
Drosophila has highlighted an interaction
between Parkin and PINK1 and pointed
to mitochondrial and dopaminergic dys-
function as possible converging mecha-
nisms in PD. Thus, an intriguing question
arises: do a-synuclein and LRRK2, the
dominant PD-linked gene products, act
together in processes relevant to PD
pathogenesis?
In this issue of Neuron, an elegant
genetic study by Lin et al. (2009) identifies
an important functional interplay between
a-synuclein and LRRK2 in the develop-
ment of neurodegeneration and other
neuropathological features caused by
a-synuclein overexpression. Using the
tetracycline-controlled transactivator sys-
tem, the authors generated a series of
inducible transgenic mice overexpressing
the human A53T mutant form of a-synu-
clein or various forms of human LRRK2,
including wild-type, G2019S, or kinase
domain-deletion mutant in the adult fore-
brain. They found that 30-fold overpro-
duction of A53T a-synuclein in the adult
forebrain results in locomotor defects in
the open field as early as 2 months of
age and age-related neurodegeneration,ecember 24, 2009 ª2009 Elsevier Inc. 771
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as well as progressive loss of cortical and
striatal neurons. 16-fold overproduction
of wild-type or G2019S mutant LRRK2,
however, does not cause neurodegenera-
tion up to 20 months of age.
Intriguingly, co-overexpression of either
wild-type or G2019S LRRK2 with A53T
a-synuclein dramatically accelerated
neurodegeneration in double-transgenic
mice. At 1 month of age, when no neu-
ropathology was detected in any of the
single-transgenic brains, increased apo-
ptosis and gliosis as well as loss of
neurons were evident in the double-trans-
genic striatum. Furthermore, the effect of
LRRK2 overexpression on neurodegener-
ative features in A53T a-synuclein trans-
genic mice is more dependent on the level
of LRRK2 overexpression than the pres-
ence of the G2019S mutation. Surpris-
ingly, LRRK2 lacking the kinase domain
also accelerated A53T a-synuclein-medi-
ated neuropathology to a similar extent
as wild-type LRRK2 when expressed at
similar levels, suggesting that the kinase
domain of LRRK2 is not essential in the
interplay of a-synuclein and LRRK2. Lin
et al. further verified that this interplay
is specific between a-synuclein and
LRRK2 by showing that co-overexpres-
sion of A53T a-synuclein with a control
protein, the green fluorescent protein
(GFP), did not accelerate the progression
of A53T a-synuclein-mediated neuropa-
thology, and that co-overexpression of
G2019S LRRK2 with a mutant version of
the amyloid precursor protein (APP) did
not accelerate APP-mediated astrocyto-
sis and microgliosis.
LRRK2 overexpression also promoted
abnormal somatic accumulation of
a-synuclein in striatal neurons of A53T
a-synuclein transgenic mice. While a-syn-
uclein is normally localized in axonal
terminals, overexpression of A53T a-syn-
uclein results in its accumulation in cell
bodies in an age-dependent manner.
Overexpression of LRRK2 in A53T a-syn-
uclein transgenic mice caused earlier
and more widespread somatic accu-
mulation of a-synuclein. LRRK2 overex-
pression also accelerated a-synuclein
aggregation, which can be detected as
high-molecular-weight species in brain
extracts from older A53T a-synuclein
or younger A53T a-synuclein/G2019S
LRRK2 transgenic mice.772 Neuron 64, December 24, 2009 ª2009 ETo explore further how LRRK2 overex-
pression promotes a-synuclein-based
neuropathology, including neurodegener-
ation and abnormal a-synuclein accu-
mulation and/or aggregation, Lin et al.
examined ER/Golgi trafficking, the ubiqui-
tin-proteasome system, and mitochon-
dria. Earlier studies have shown that
overexpression of a-synuclein resulted in
blocked ER/Golgi vesicular trafficking in
yeast and Golgi fragmentation in cultured
cells (Cooper et al., 2006; Gosavi et al.,
2002). While the ER structure appeared
normal, immunohistochemical analysis
with specific markers showed that the
Golgi complex was disrupted in striatal
neurons of young A53T a-synuclein/
LRRK2 transgenic mice. Both cis- and
medial/trans-Golgi networks were drasti-
cally altered in various single-transgenic
mice, with the exception of A53T a-synu-
clein mice, in which the cis-Golgi system
appeared normal, and were further dis-
rupted in double transgenic mice. Addi-
tional investigation revealed a perturbed
dynamics of microtubule assembly with
a shift from free tubulin to polymerized
tubulin in LRRK2 but notA53T a-synuclein
transgenic mice. This perturbation of the
microtubule network was thought to
underlie the disrupted structure of the
Golgi apparatus. However, it is somewhat
puzzling why overexpression of LRRK2
alone was sufficient to cause disruption
of the microtubule network and Golgi
apparatus but insufficient to cause neuro-
degeneration, whereas A53T a-synuclein
transgenic mice exhibited much subtler
microtubule and Golgi phenotypes but
striking neuronal degeneration. Co-over-
expression of A53T a-synuclein and
G2019S LRRK2 also appeared to have
caused increases in ubiquitin-positive
aggregates and abnormal mitochondria.
The last piece of data provided perhaps
the most important supporting evidence
for the major conclusions of the paper,
showing that genetic deletion of LRRK2
ameliorated neurodegeneration, gliosis,
a-synuclein aggregation, and the Golgi
phenotypes in A53T a-synuclein trans-
genic mice. Given the very high levels of
the transgene expression (30-fold for
A53T a-synuclein, and 16-fold for wild-
type and G2019S LRRK2) and the lack
of significant differences between wild-
type and G2019S LRRK2 on their modula-
tion of a-synuclein-mediated neuropatho-lsevier Inc.logical changes, a valid concern was that
the observed phenotypes could be simply
due to overproduction of the proteins
expressed from the transgenes. Inclusion
of transgenic mice overexpressing GFP or
APP as controls dispelled some of the
concerns, though understandably these
control mice were not analyzed as
exhaustively. The fact that inactivation of
LRRK2 rescues the loss of striatal
neurons in A53T a-synuclein transgenic
mice provides key support for a regulatory
role of LRRK2 in a-synuclein-mediated
neuropathology under overexpression
conditions.
The findings in Lin et al. highlight an
important interplay between two domi-
nant PD gene products of a-synuclein
and LRRK2. However, many questions
remain. How does LRRK2 regulate the
dynamics of the microtubule network?
Are tubulins or microtubule-binding pro-
teins physiological substrates of LRRK2’s
kinase activity? It will be important to
determine by electron microscopy the
ultrastructure of the Golgi apparatus
and the subcellular localization of a-synu-
clein in the various single and double
A53T a-synuclein and LRRK2 mutant
mice described in the current report.
Such analysis may help to explain why
LRRK2 transgenic mice exhibit severe
Golgi defects but no neurodegeneration,
whereas A53T a-synuclein transgenic
mice conversely show subtle Golgi
phenotypes but striking neurodegenera-
tion. In addition, it would be interesting
to evaluate whether the ER/Golgi traf-
ficking and microtubule network are dis-
rupted in the recently reported LRRK2
transgenic and knockin mice, which
could contribute to the dopamine release
defect in these mice (Li et al., 2009; Tong
et al., 2009). Furthermore, it remains to
be determined whether the microtubule
network and the Golgi apparatus are
affected in the absence of LRRK2. Lastly,
it is important to establish whether the
interplay between LRRK2 and a-synuclein
is limited to overexpression conditions,
and whether LRRK2 can interact with
endogenous a-synuclein under physio-
logical conditions.
As the authors rightly point out, while
A53T a-synuclein/LRRK2 transgenic
mice provide very useful models to study
the mechanisms of neurodegeneration
and the genetic interaction between
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Previewsa-synuclein and LRRK2, the occurrence
of neurodegeneration in cortical and
striatal neurons of the forebrain in these
transgenic mice limits their relevance to
PD pathogenesis. Thus, the generation
of inducible transgenic mice targeting
a-synuclein overexpression to DA neurons
of the SNpc would enable investigation of
the key mechanisms by which a-synuclein
aggregation may lead to dysfunction and
degeneration of DA neurons. In addition,
inducible DA neuron-specific a-synuclein
transgenic mice could then be crossed
with LRRK2 mutant mice carrying either
pathogenic missense or null mutations
to study how LRRK2 interacts with a-syn-
uclein in the regulation of DA neuronal
dysfunction and degeneration. Such inno-
vative mouse models would provide
a valuable platform for further mecha-
nistic studies aimed at uncovering themolecular basis of DA neurodegeneration
and developing improved therapeutic
strategies.REFERENCES
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The rapidly adapting (RA) low-threshold mechanoreceptors respond to movement of the skin and vibration
and are critical for the perception of texture and shape. In this issue ofNeuron, two papers (Bourane et al. and
Luo et al.) demonstrate that early-born Ret+ sensory neurons are RA mechanoreceptors, whose peripheral
nerve terminals are associated with Meissner corpuscles, longitudinal lanceolate endings, and Pacinian
corpuscles. The studies further show that Ret signaling is essential for the development of these mechano-
receptors.In mammals, sensory neurons in the dorsal
root ganglia (DRG) and trigeminal ganglia
detect a widevariety of mechanical stimuli,
and they are critical for the perception of
touch, body positions, and pain. In this
preview, we focus on low-threshold mech-
anoreceptors whose peripheral terminals
are associated with specialized end-
organs in the skin or the deep tissues
(Rice and Albrecht, 2008; Lewin and
Moshourab, 2004; Montan˜o et al., 2009;
Tsunozaki and Bautista, 2009). Based on
adaptation rates in response to sustained
mechanical stimuli, these mechanorecep-
tors are divided into rapidly adapting (RA)and slowly adapting (SA) subtypes. In
mice, RA mechanoreceptors terminate
as Meissner corpuscles in the dermal
papillae, longitudinal lanceolate endings
in hair follicles, and Pacinian corpuscles
in the joints and the periostea of bones;
these neurons respond to movement of
the skin, vibration, and the onset/offset of
sustained indentation. SA mechanorecep-
tors innervate the Merkel discs and Ruffini
corpuscles, and respond to skin move-
ment and static indentation stretch.
Collectively, these mechanoreceptors are
critical for the discriminative perception
of texture, shape, vibration, and pressure.Despite extensive morphological and
electrophysiological characterizations,
developmental ontogeny and molecular
identities of RA versus SA mechanore-
ceptors are still poorly studied. A few
studies have implicated a crucial role for
neurotrophic factors in the development
of specific subtypes of RA or SA mecha-
noreceptors. For example, the neurotro-
phin NT3 is required to maintain Merkel
cells and nerve terminals from SA mecha-
noreceptors (Airaksinen et al., 1996). In
another example, BDNF-mediated TrkB
signaling is critical for the formation of
Meissner corpuscles but is dispensableecember 24, 2009 ª2009 Elsevier Inc. 773
